Sentences with phrase «derived islet cell»
The Company's pluripotent stem cell - derived islet cell replacement therapy, the PEC - Direct ™ product candidate, has the potential to be a breakthrough treatment for high - risk type 1 diabetes.
http://viacyte.com/
ViaCyte's PEC - EncapTM (also known as VC - 01TM) product candidate is the first pluripotent stem cell - derived islet cell replacement therapy for the treatment of type 1 diabetes in clinical - stage development.
In pre-clinical experiments, hESC - derived cardiomyocytes engraft in damaged myocardium and appear to behave like native cells; hESC - derived islet cells engraft, produce the hormones of the endocrine pancreas, and appear to do so under homeostatic control; etc. \ n \ nThere is no evidence of teratomas from differentiated hESC - derived cells and minimal, if any, immune rejection.
Not exact matches
This is an image of human stem cell - derived beta cells that have formed islet like clusters in a mouse.
At the annual meeting of the American Diabetes Society in Washington, D.C., researchers from the medical schools of Keio and Osaka universities reported that they had substituted a tumor - derived islet for Faustman's spleen cells.
«ViaCyte was the first to differentiate human stem cells into glucose - responsive, insulin - producing cells, and now we are running the first and only clinical trials of stem cell - derived islet replacement therapies for type 1 diabetes,» said Paul Laikind, PhD, President and CEO of ViaCyte.
Review of «Tumor - Free Transplantation of Patient - Derived Induced Pluripotent Stem Cell Progeny for Customized Islet Regeneration» from Stem Cells Translational Medicine by Stuart P. Atkinson
In addition, ViaCyte launched the first clinical trials for stem cell - derived islet replacement therapies for type 1 diabetes.
Tumor - Free Transplantation of Patient - Derived Induced Pluripotent Stem Cell Progeny for Customized Islet Regeneration.
SAN DIEGO and BETHESDA, MD, March 3, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Eugene Brandon, Director of Strategic Relations and Project Management, at the JDRF TypeOneNation Summit.
SAN DIEGO, April 20, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced four presentations at upcoming healthcare events.
Maturation of human embryonic stem cell - derived pancreatic progenitors into functional islets capable of treating pre-existing diabetes in mice.
Exploitation of alternative cell sources (xenogeneic primary islets, stem cell derived beta cells) for utilization in our encapsulation device (collaboration with Anthony Gavalas, CRTD)
Novocell also demonstrated earlier this year, that hES - derived pancreatic progenitorsdevelop into human islet cells capable of producing insulin in response to glucose and ameliorating diabetes in animal models.
SAN DIEGO, September 9, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced participation on a panel at the 2016 BioPharm ™ America — 9th Annual International Partnering Conference.
SAN DIEGO, March 17, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Paul Laikind, President and CEO, at the third annual Regen Med Investor Day co-hosted by the Alliance for Regenerative Medicine (ARM) and top financial firm Piper Jaffray.
In addition, the funding will be used to support other operations including the continued development of the PEC - Encap ™ product candidate, ViaCyte's stem cell - derived islet replacement therapy that is being developed as a treatment for all diabetes patients who require insulin to control their disease.
In addition to iPS cells derived from progeria - patients, the researchers successfully applied their method to adult mesenchymal stem cells, which can differentiate into a variety of cell types, including adipocytes, osteoblasts, chondrocytes, cardiomyocytes, and, as described lately, beta - pancreatic islets cells.
San Diego, January 8, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's Phase 1/2 clinical trial of its VC - 01TM product candidate.
San Diego, California, October 6, 2014 — ViaCyte, Inc., a privately - held regenerative medicine company developing a stem cell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follcell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follCell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follows:
SAN DIEGO, March 1, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced presentations at the JDRF TypeOneNation Summit meetings being held in Washington DC and Los Angeles.
Creation of a rich subcutaneous vascular network with implanted adipose tissue - derived stromal cells and adipose tissue enhances subcutaneous grafting of islets in diabetic mice.
The PEC - Encap (also known as VC - 01) product candidate is designed to deliver stem cell - derived islet replacement therapies to patients with type 1 diabetes as well as patients with type 2 disease that require insulin.
The VC - 01 product candidate is the first embryonic stem cell - derived islet replacement therapy to reach clinical testing and is currently being evaluated in patients with T1D who have minimal to no insulin - producing beta cell function.
SAN DIEGO, June 22, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced two presentations at ISSCR 2016 Annual Meeting.
«The efficient production of endoderm represents the first critical step in the creation of a renewable islet source derived from hES cells that is targeted at restoring normal glucose regulation in diabetic patients.»
«Novocell is a leader in differentiation of stem cells to create functional islet cells of the pancreas, and this broad patent significantly enhances our proprietary position and further secures our investment in the development of a diabetes cell therapy and potentially other endoderm - derived cell products,» said Edward Baetge, Ph.D., Senior Vice President and Chief Scientific Officer of Novocell.